Severe chemotherapy-induced diarrhea in patients with colorectal cancer: A cost of illness analysis

Supportive Care in Cancer

Volumn 13, Issue 5, 2005, Pages 318-324

  Dranitsaris, George ^a   Maroun, Jean ^b   Shah, Amil ^c  

^a CANCER CARE ONTARIO   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c Canadian Centre for Applied Research in Cancer Control   (Canada)

Author keywords

Chemotherapy; Colorectal cancer; Cost analysis; Diarrhea

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ECONOMIC ASPECT; FEMALE; HEALTH CARE MANAGEMENT; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; COLORECTAL NEOPLASMS; COST OF ILLNESS; DIARRHEA; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 18744409081     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0738-7     Document Type: Article

References (12)

1. Arbuckle RB, Huber SL, Zacker C (2000) The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5:250-259
2. Cancer Therapy Evaluation Program, National Cancer Institute (1999) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda: National Institutes of Health, U.S. Department of Health and Human Services
3. de Gramont A, Seymour AF, Homerin M, et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
4. Douillard JY, Cunningham D, Roth AD, et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041-1047
5. Doyle C, Stockler M, Pintilli M, et al (1997) Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 15:1000-1007
6. Goldberg RM, Sargent DJ, Morton RF, et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
7. Grem JL, Shoemaker DD, Patrelli NJ, et al (1987) Severe life threatening toxicities observed using leucovorin with 5-fluorouracil. J Clin Oncol 5:1704-1712
8. Moertel CG, Fleming TR, Macdonald JS, et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321-326
9. Rosenoff S (2003) Octreotide LAR resolves severe chemotherapy-induced diarrhea (CID) and allows continuation of full-dose therapy. Proc Am Soc Clin Oncol 22 (abstract 3126)
10. Tournigand C, Andre T, Achille E, et al (2004) FOLFIRI followed by FOL FOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
11. Wadler S, Benson AB 3rd, Engelking C, et al (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16:3169-3178
12. Zaniboni A (1997) Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 15:2432-2441